Icrucumab
Based on 1 publication(s) in Google Scholar
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting VEGFR-1/FLT1 with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer.
For research use only. We do not sell to patients.
- Purity: 99.9%
- CAS No.: 1024603-92-6
- Molecular Weight:146.68 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Icrucumab
MoreAll VEGFR Isoforms
More
Biological Activity
Human IgG1 kappa
Human
VEGFR1/FLT1
Icrucumab (30 μg/mL) attenuates Dexamethasone (HY-14648)-mediated conversion of M1 macrophages to an M2-like phenotype by inhibiting FLT-1 (VEGFR-1), increases the expression of M1 markers and decreases the expression of M2 markers, thereby regulating the polarization of tumor-associated macrophages and indirectly affecting tumor progression[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized VEGFR-1 Protein, Human (328a.a, HEK293, His, HY-P73065) can bind Icrucumab. The EC50 for this effect is 5.461 ng/mL. -
Flow cytometric analysis of 1X106 HUVEC cells with Icrucumab (HY-P99364, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1024603-92-6
-
Appearance Liquid
-
Molecular Weight 146.68 kDa
-
Color Colorless to light yellow
-
SMILES
[Icrucumab]
-
Synonyms
Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Dis
Dexamethasone drives macrophage repolarization linked to increased triple-negative breast cancer aggressiveness. [Abstract]2025 Dec 19. PMID: 41413093
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)